Denali Capital Acquisition Corp.
DECAU
NASDAQ Global Market11.84
USD
- -
- -
CIK
0001913577
ISIN
KYG6256B1225
CUSIP
G6256B122
Return %
Stock
S&P500
1Y
33.63
26.53
3Y
18.16
76.60
5Y
18.16
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lei Huang
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 437 Madison Avenue New York City NY United States of America 10022
- IPO Date
- Apr 7, 2022
- CIK
- 0001913577
- Similar Companies
- Business
- Denali Capital Acquisition Corp. (DECAU) operates as a blank check company, or special purpose acquisition company (SPAC), whose primary business is to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses, with a focus on high-growth targets in the technology, consumer services, and hospitality sectors; it issues units comprising Class A ordinary shares and redeemable warrants, which commenced separate trading in 2022. Incorporated in 2022 and headquartered at 437 Madison Avenue, 27th Floor, New York, New York, the company maintains no significant independent operations prior to completing an initial business combination and targets institutional and accredited investors through its public offerings. Geographically, it conducts activities primarily from the United States, with its securities listed on Nasdaq and subsequently OTC markets under symbols DECAU for units, DECA or DNQAF for Class A ordinary shares, and DECAW or DNQWF for warrants. In a major development, Denali completed a reverse merger with Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX) focused on non-opioid pain therapies, on September 22, 2025, following an original merger agreement signed August 30, 2024, valued at a $2.5 billion pre-transaction equity value for Semnur, with subsequent amendments on April 16, 2025, and July 22, 2025, including extensions of its business combination deadline through January 2025 via trust deposits funded by convertible notes from Scilex; post-merger, Semnur trades as SMNR on OTC markets, domesticating Denali to Delaware and renaming it Semnur Pharmaceuticals, Inc., while filing an S-4 registration for new shares, preferred stock, and warrants.